Prednisolone

Evidence Level: L2

Predicted Indications: 9

Prednisolone

Pharmacist Assessment Report

Prednisolone: From Autoimmune Disease to Alopecia Areata

One-Sentence Summary

Prednisolone is a glucocorticoid, originally used for autoimmune and inflammatory conditions such as Crohn disease, inflammatory bowel disease, adrenocortical insufficiency and acute lymphoblastic leukaemia. The TxGNN model predicts it may be effective for Alopecia Areata. No clinical trials are registered for this indication, but 20 publications support the direction, including a placebo-controlled RCT and several systematic reviews.

Quick Overview

Item	Content
Original Indication	Autoimmune disease (the licence records in the compiled data contain no approved indication text)
Predicted New Indication	Alopecia areata
TxGNN Prediction Score	0.9999
Evidence Level	L2
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, prednisolone is a systemic glucocorticoid. Its efficacy in autoimmune and inflammatory diseases is well established, and mechanistically it may be applicable to alopecia areata.

Alopecia areata is a T-cell-mediated autoimmune attack on the hair follicle, with collapse of follicular immune privilege. Glucocorticoids suppress T-cell activation and pro-inflammatory cytokine production, which directly targets this pathway. This fits the drug’s existing autoimmune uses. One study also suggests that oral pulse steroids lower serum and tissue TNF-α levels in alopecia areata (PMID 30294905).

Practical limits apply. Hair loss often relapses after withdrawal, and cumulative steroid toxicity restricts long-term use. JAK inhibitors are now preferred where available. Prednisolone is therefore best positioned as short-course or pulse therapy, or as an option when JAK inhibitors are unsuitable.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15692475	2005	RCT	J Am Acad Dermatol	Placebo-controlled study of oral pulse prednisolone in alopecia areata
37870096	2023	Network meta-analysis	Cochrane Database Syst Rev	Compares treatments for alopecia areata, including immunosuppressants, hair growth stimulants and contact immunotherapy
30191561	2019	Systematic review	Australas J Dermatol	Evidence for systemic treatments in alopecia areata, totalis and universalis; efficacy varies
37992355	2023	Review	Dermatol Pract Concept	Efficacy, relapse rates, side effects and prognostic factors of corticosteroid pulse therapy
36461625	2023	Review	Pediatr Dermatol	Dosing regimens and side effects of pulse corticosteroids in children
21572877	2009	Cohort	Dermato-endocrinology	Medium-dose prednisolone pulse therapy appears effective early on, but side effects may lead to discontinuation
28140540	2017	Cohort	J Dtsch Dermatol Ges	Sequential high- then low-dose steroids in severe childhood alopecia areata
32779249	2020	Retrospective study	J Eur Acad Dermatol Venereol	Azathioprine, methotrexate and cyclosporine as steroid-sparing agents in 138 patients with chronic disease
41243342	2025	Case report	J Dermatol Treat	Durable remission with dexamethasone oral mini-pulse when JAK inhibitors were unsuitable
30294905	2019	Mechanistic study	J Cosmet Dermatol	Changes in TNF-α levels as a possible mechanism of oral pulse steroids

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
152780	Nisolone 5mg Tablet	Strip of 10 tablets	Not specified in the data
174223	Pred 10mg Tablet	Strip of 10 tablets	Not specified in the data
161855	Omnacortil 30 Tablet DT	Strip of 10 dispersible tablets	Not specified in the data
99146	GB Pred AC Eye Drop	Bottle of 5 ml eye drop	Not specified in the data
39969	Ceruclean Drop	Packet of 10 ml drop	Not specified in the data

There are 20 valid single-ingredient licences in total, mostly oral tablets, plus eye and ear/other drops.

Safety Considerations

Drug Interactions: The data compiled for this report list 753 interacting drugs. Examples:

Major: adalimumab
Moderate: zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, butalbital, albiglutide, aldesleukin, alemtuzumab, aliskiren, tetanus toxoid vaccine
Minor: formoterol, salbutamol

Disease-level contraindication signals (knowledge graph, not label text): hypertension, epilepsy, hyperglycaemia, congestive heart failure, herpes simplex keratitis, measles, porphyria, certain urea cycle disorders (e.g., citrullinemia, hyperargininemia) and pituitary hormone deficiencies.

Literature also notes relapse after withdrawal and cumulative steroid toxicity. For complete warnings, please refer to the package insert.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A placebo-controlled RCT, multiple cohort studies and systematic reviews support pulse corticosteroids in alopecia areata, and the mechanism is plausible. However, no registered trials were found, relapse after withdrawal is common, and JAK inhibitors are preferred where available.

To proceed, the following is needed:

Package insert warnings and contraindications from the Indian regulator (currently missing, and blocking safety screening)
Detailed mechanism of action data
Review of the primary trial data to confirm effect size and relapse rates
A pulse-dosing protocol with monitoring for blood pressure, glucose, infection and bone health, and consideration of steroid-sparing agents
Confirmation of approved indication text for the Indian licences
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.